Ocuphire Pharma Analyst Ratings
Ocuphire Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/14/2023 | 457.38% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/16/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/31/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 01/26/2023 | 555.74% | HC Wainwright & Co. | $26 → $20 | Maintains | Buy |
| 11/24/2021 | 752.46% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/05/2021 | 719.67% | Alliance Global Partners | → $25 | Initiates Coverage On | → Buy |
| 03/29/2021 | 555.74% | JonesTrading | → $20 | Initiates Coverage On | → Buy |
| 03/15/2021 | 555.74% | Cantor Fitzgerald | $15 → $20 | Maintains | Overweight |
| 02/10/2021 | 621.31% | Canaccord Genuity | → $22 | Initiates Coverage On | → Buy |
| 11/20/2020 | 391.8% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 08/14/2023 | 457.38% | 坎託·菲茨傑拉德 | → 17 美元 | 重申 | 超重 → 超重 |
| 08/14/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 05/16/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 03/31/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 02/17/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 01/26/2023 | 555.74% | HC Wainwright & Co. | 26 美元 → 20 美元 | 維護 | 買 |
| 11/24/2021 | 752.46% | HC Wainwright & Co. | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/05/2021 | 719.67% | 聯盟全球合作伙伴 | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/29/2021 | 555.74% | JonesTrading | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 3 月 15 日 | 555.74% | 坎託·菲茨傑拉德 | 15 美元 → 20 美元 | 維護 | 超重 |
| 2021 年 10 月 2 日 | 621.31% | Canaccord Genu | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/20/2020 | 391.8% | 坎託·菲茨傑拉德 | → 15 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Ocuphire Pharma (OCUP)?
Ocuphire Pharma（OCUP）的目標價格是多少？
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $20.00 expecting OCUP to rise to within 12 months (a possible 555.74% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月14日公佈了Ocuphire Pharma（納斯達克股票代碼：OCUP）的最新目標股價。該分析公司將目標股價定爲20.00美元，預計OCUP將在12個月內升至12個月內（可能上漲555.74％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Ocuphire Pharma (OCUP)?
分析師對Ocuphire Pharma（OCUP）的最新評級是多少？
The latest analyst rating for Ocuphire Pharma (NASDAQ: OCUP) was provided by HC Wainwright & Co., and Ocuphire Pharma reiterated their buy rating.
Ocuphire Pharma（納斯達克股票代碼：OCUP）的最新分析師評級由HC Wainwright & Co. 提供，Ocuphire Pharma重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Ocuphire Pharma (OCUP)?
Ocuphire Pharma（OCUP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocuphire Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocuphire Pharma was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Ocuphire Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Ocuphire Pharma的最新評級是在2023年11月14日公佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Ocuphire Pharma (OCUP) correct?
分析師對Ocuphire Pharma（OCUP）的評級正確嗎？
While ratings are subjective and will change, the latest Ocuphire Pharma (OCUP) rating was a reiterated with a price target of $0.00 to $20.00. The current price Ocuphire Pharma (OCUP) is trading at is $3.05, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Ocuphire Pharma（OCUP）評級，目標股價爲0.00美元至20.00美元。Ocuphire Pharma（OCUP）目前的交易價格爲3.05美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。